Many studies have correlated the presence of a BRAF mutation in advanced CRC with metastatic disease, poor outcomes following oncological treatment, and reduced overall survival when compared with BRAFWT (wild-type) disease [8–10]. The gene discussed is BRAF; the disease is colorectal carcinoma.